Tissue Microarray Is a Reliable Tool for the Evaluation of HER2 Amplification in Breast Cancer

被引：7

作者：

Furrer, Daniela ^{[1
,2
,3
]}

Jacob, Simon ^{[4
,6
,7
]}

Caron, Chantal ^{[6
,7
]}

Sanschagrin, Francois ^{[2
,6
]}

Provencher, Louise ^{[2
,5
,6
]}

Diorio, Caroline ^{[1
,2
,3
,6
]}

机构：

[1] Univ Laval, Canc Res Ctr, Quebec City, PQ, Canada

[2] CHU Quebec Res Ctr, Oncol Axis, Quebec City, PQ, Canada

[3] Univ Laval, Dept Social & Prevent Med, Fac Med, Quebec City, PQ, Canada

[4] Univ Laval, Dept Mol Biol Med Biochem & Pathol, Fac Med, Quebec City, PQ, Canada

[5] Univ Laval, Dept Surg, Fac Med, Quebec City, PQ, Canada

[6] St Sacrement Hosp, Deschenes Fabia Ctr Breast Dis, Quebec City, PQ, Canada

[7] St Sacrement Hosp, Pathol Serv, Quebec City, PQ, Canada

来源：

ANTICANCER RESEARCH | 2016年 / 36卷 / 09期

关键词：

Breast cancer; trastuzumab; TMA; ASCO/CAP guidelines; HER2; status; FISH; IN-SITU HYBRIDIZATION; FACTOR RECEPTOR 2; GROWTH-FACTOR; GENE AMPLIFICATION; PROTEIN EXPRESSION; VALIDATION; TECHNOLOGY; IMMUNOHISTOCHEMISTRY; CARCINOMA; RELIABILITY;

D O I：

10.21873/anticanres.11017

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Aim: We examined an economical method for evaluating the amplification of the human epidermal growth factor receptor 2 (HER2) gene in breast cancer specimens. Materials and Methods: We compared HER2 amplification determined by fluorescence in situ hybridization (FISH) on whole-tissue (WT) blocks used for diagnostic and on tissue microarray (TMA) sections for a cohort of 521 consecutive patients with breast cancer. In a subset of 116 patients, we examined HER2 concordance from the WT section and a TMA section from a randomly chosen additional block (a proxy of the core biopsy). Results: Overall concordance for HER2 amplification between WT and TMA sections was 98.2%, and between sections from WT and from the additional block was 99.0%. Conclusion: The high concordance rates support the use of TMA for the evaluation of HER2 amplification in breast cancer and suggest that FISH can be used to assess HER2 using core biopsies.

引用

页码：4661 / 4666

页数：6

共 27 条

[1] Comparison of fluorescent in situ hybridization HER-2/neu results on core needle biopsy and excisional biopsy in primary breast cancer [J].

Apple, Sophia K. ;

Lowe, Alarice C. ;

Rao, P. Nagesh ;

Shintaku, I. Peter ;

Moatamed, Neda A. .

MODERN PATHOLOGY, 2009, 22 (09) :1151-1159

[2] Multicentric/multifocal breast cancer with a single histotype: is the biological characterization of all individual foci justified? [J].

Buggi, F. ;

Folli, S. ;

Curcio, A. ;

Casadei-Giunchi, D. ;

Rocca, A. ;

Pietri, E. ;

Medri, L. ;

Serra, L. .

ANNALS OF ONCOLOGY, 2012, 23 (08) :2042-2046

[3] Validation of tissue microarray technology in breast carcinoma [J].

Camp, RL ;

Charette, LA ;

Rimm, DL .

LABORATORY INVESTIGATION, 2000, 80 (12) :1943-1949

[4] The hormone receptor, human epidermal growth factor receptor 2, and molecular subtype status of individual tumor foci in multifocal/multicentric invasive ductal carcinoma of breast [J].

Choi, Yoomi ;

Kim, Eun Joo ;

Seol, Hyesil ;

Lee, Hee Eun ;

Jang, Mi Jung ;

Kim, Sun Mi ;

Kim, Jee Hyun ;

Kim, Sung-Won ;

Choe, Gheeyoung ;

Park, So Yeon .

HUMAN PATHOLOGY, 2012, 43 (01) :48-55

[5] Virtual microscopy as an enabler of automated/quantitative assessment of protein expression in TMAs [J].

Conway, Catherine ;

Dobson, Lynne ;

O'Grady, Anthony ;

Kay, Elaine ;

Costello, Sean ;

O'Shea, Daniel .

HISTOCHEMISTRY AND CELL BIOLOGY, 2008, 130 (03) :447-463

[6] Accurately Assessing HER-2/neu Status in Needle Core Biopsies of Breast Cancer Patients in the Era of Neoadjuvant Therapy: Emerging Questions and Considerations Addressed [J].

D'Alfonso, Timothy ;

Liu, Yi-Fang ;

Monni, Stefano ;

Rosen, Paul Peter ;

Shin, Sandra J. .

AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2010, 34 (04) :575-581

[7] Molecular predictors of response to trastuzumab and lapatinib in breast cancer [J].

Esteva, Francisco J. ;

Yu, Dihua ;

Hung, Mien-Chie ;

Hortobagyi, Gabriel N. .

NATURE REVIEWS CLINICAL ONCOLOGY, 2010, 7 (02) :98-107

[8] Validation of tissue microarray technology in endometrioid cancer of the endometrium [J].

Fons, Guus ;

Hasibuan, Siti M. ;

van der Velden, Jacobus ;

ten Kate, Fiebo J. W. .

JOURNAL OF CLINICAL PATHOLOGY, 2007, 60 (05) :500-503

[9] Advantages and Disadvantages of Technologies for HER2 Testing in Breast Cancer Specimens [J].

Furrer, Daniela ;

Sanschagrin, Francois ;

Jacob, Simon ;

Diorio, Caroline .

AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2015, 144 (05) :686-703

[10] Reliability of the tissue microarray based FISH for evaluation of the HER-2 oncogene in breast carcinoma [J].

Gancberg, D ;

Di Leo, A ;

Rouas, G ;

Järvinen, T ;

Verhest, A ;

Isola, J ;

Piccart, MJ ;

Larsimont, D .

JOURNAL OF CLINICAL PATHOLOGY, 2002, 55 (04) :315-317

← 1 2 3 →